35Pharma Closes Series C Financing to Advance Clinical Pipeline of Activin Inhibitors for Pulmonary Hypertension, Cardiometabolic Disease and Obesity
Summary
Financing led by Frazier Life Sciences with participation from new investors including Vivo Capital, Janus Henderson Investors, Deep Track Capital, Paradigm BioCapital Advisors and Columbia ThreadneedleMONTREAL, Nov. 26, 2024 (GLOBE NEWSWIRE) -- 35Pharma, a clinical-stage biopharmaceutical company developing TGF-beta superfamily therapeutics, today announced the closing of an oversubscribed $53 million Series C financing. "We are delighted to close this Series C financing, which brings multiple new marquee healthcare investors into our cap table," said Ilia A. Tikhomirov, CEO of 35Pharma. ""Targeting Activin- and GDF-mediated signaling has emerged as an important therapeutic approach across cardiometabolic and pulmonary disease," said Kevin Li, M.D., Principal at Frazier Life Sciences. Frazier Life Sciences is pleased to support the team in advancing their pipeline through the clinic, and toward the goal of transforming the standard of care in pulmonary hypertension, obesity, and heart failure. "About 35Pharma35Pharma is a clinical-stage biopharmaceutical company focused on developing best-in-class transforming growth factor-beta (TGF-beta) superfamily ligand traps for pulmonary hypertension, obesity and cardiometabolic diseases.